메뉴 건너뛰기
OncoImmunology
Volumn 5, Issue 9, 2016, Pages
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
Author keywords

DC; Dendritic cell; electroporation; melanoma; metronomic cyclophosphamide; mRNA; vaccination
Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 RECEPTOR; TIM 3 PROTEIN; UNCLASSIFIED DRUG;
EID: 84988874485     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1207842     Document Type: Article
Times cited : (32)
References (46)
  • 1
    • 84928917822 scopus 로고    scopus 로고
    • Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma
    • D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
    • (2015) J Clin Oncol , vol.33 , pp. 1889-1894
    • Schadendorf, D.1    Hodi, F.S.2    Robert, C.3    Weber, J.S.4    Margolin, K.5    Hamid, O.6    Patt, D.7    Chen, T.T.8    Berman, D.M.9    Wolchok, J.D.10
  • 2
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma
    • 26027431
    • J.Larkin, S.Hodi, J.D.Wolchok. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
    • (2015) N Engl J Med , vol.373 , pp. 23-34
    • Larkin, J.1    Hodi, S.2    Wolchok, J.D.3
  • 4
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • 24714771
    • J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-5074; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
    • (2014) Clin Cancer Res , vol.20 , pp. 5064-5074
    • Taube, J.M.1    Klein, A.2    Brahmer, J.R.3    Xu, H.4    Pan, X.5    Kim, J.H.6    Chen, L.7    Pardoll, D.M.8    Topalian, S.L.9    Anders, R.A.10
  • 5
    • 84991030732 scopus 로고    scopus 로고
    • Rational combinations of immunotherapeutics that target discrete pathways
    • 24829752
    • S.Spranger, T.Gajewski. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 2013; 1:16; PMID:24829752; http://dx.doi.org/10.1186/2051-1426-1-16
    • (2013) J Immunother Cancer , vol.1 , pp. 16
    • Spranger, S.1    Gajewski, T.2
  • 6
    • 84867552067 scopus 로고    scopus 로고
    • Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
    • 22426890
    • E.Ellebaek, L.Engell-Noerregaard, T.Z.Iversen, T.M.Froesig, S.Munir, S.R.Hadrup, M.H.Andersen, I.M.Svane. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide:results from a phase II trial. Cancer Immunol Immunother 2012; 61:1791-804; PMID:22426890; http://dx.doi.org/10.1007/s00262-012-1242-4
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 1791-1804
    • Ellebaek, E.1    Engell-Noerregaard, L.2    Iversen, T.Z.3    Froesig, T.M.4    Munir, S.5    Hadrup, S.R.6    Andersen, M.H.7    Svane, I.M.8
  • 7
    • 56749085780 scopus 로고    scopus 로고
    • Studies on mRNA electroporation of immature and mature dendritic cells: Effects on their immunogenic potential
    • 18543130
    • Ö.Met, J.Eriksen, I.M.Svane. Studies on mRNA electroporation of immature and mature dendritic cells:Effects on their immunogenic potential. Mol Biotechnol 2008; 40:151-160; PMID:18543130; http://dx.doi.org/10.1007/s12033-008-9071-6
    • (2008) Mol Biotechnol , vol.40 , pp. 151-160
    • Met, Ö.1    Eriksen, J.2    Svane, I.M.3
  • 8
    • 78650992314 scopus 로고    scopus 로고
    • High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer
    • 20336365
    • Ö.Met, E.Balslev, H.Flyger, I.M.Svane. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 2011; 125:395-406; PMID:20336365; http://dx.doi.org/10.1007/s10549-010-0844-9
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 395-406
    • Met, Ö.1    Balslev, E.2    Flyger, H.3    Svane, I.M.4
  • 9
    • 84857789296 scopus 로고    scopus 로고
    • The secret ally: Immunostimulation by anticancer drugs
    • 22301798
    • L.Galluzzi, L.Senovilla, L.Zitvogel, G.Kroemer. The secret ally:Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-233; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
    • (2012) Nat Rev Drug Discov , vol.11 , pp. 215-233
    • Galluzzi, L.1    Senovilla, L.2    Zitvogel, L.3    Kroemer, G.4
  • 11
    • 2442647551 scopus 로고    scopus 로고
    • Dendritic cell immunotherapy: mapping the way
    • 15122249
    • C.G.Figdor, I.J.M.de Vries, W.J.Lesterhuis, C.J.Melief. Dendritic cell immunotherapy:mapping the way. Nat Med 2004; 10:475-480; PMID:15122249; http://dx.doi.org/10.1038/nm1039
    • (2004) Nat Med , vol.10 , pp. 475-480
    • Figdor, C.G.1    de Vries, I.J.M.2    Lesterhuis, W.J.3    Melief, C.J.4
  • 12
    • 77957319524 scopus 로고    scopus 로고
    • Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
    • 20429791
    • R.Trepiakas, A.Berntsen, S.R.Hadrup, J.Bjørn, P.F.Geertsen, P.T.Straten, M.H.Andersen, A.E.Pedersen, A.Soleimani, T.Lorentzen et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma:results from a phase I/II trial. Cytotherapy 2010; 12:721-734; PMID:20429791; http://dx.doi.org/10.3109/14653241003774045
    • (2010) Cytotherapy , vol.12 , pp. 721-734
    • Trepiakas, R.1    Berntsen, A.2    Hadrup, S.R.3    Bjørn, J.4    Geertsen, P.F.5    Straten, P.T.6    Andersen, M.H.7    Pedersen, A.E.8    Soleimani, A.9    Lorentzen, T.10
  • 18
    • 84997606127 scopus 로고    scopus 로고
    • Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma
    • 26885372
    • K.Woods, A.J.Knights, M.Anaka, R.B.Schittenhelm, A.W.Purcell, A.Behren, J.Cebon. Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. J Immunother Cancer 2016; 4:10; PMID:26885372; http://dx.doi.org/10.1186/s40425-016-0111-7
    • (2016) J Immunother Cancer , vol.4 , pp. 10
    • Woods, K.1    Knights, A.J.2    Anaka, M.3    Schittenhelm, R.B.4    Purcell, A.W.5    Behren, A.6    Cebon, J.7
  • 20
    • 24944546501 scopus 로고    scopus 로고
    • Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome
    • 16110035
    • I.J.De Vries, M.R.Bernsen, W.J.Lesterhuis, N.M.Scharenborg, S.P.Strijk, M.J.Gerritsen, D.J.Ruiter, C.G.Figdor, C.J.Punt, G.J.Adema. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779-5787; PMID:16110035; http://dx.doi.org/10.1200/JCO.2005.06.478
    • (2005) J Clin Oncol , vol.23 , pp. 5779-5787
    • De Vries, I.J.1    Bernsen, M.R.2    Lesterhuis, W.J.3    Scharenborg, N.M.4    Strijk, S.P.5    Gerritsen, M.J.6    Ruiter, D.J.7    Figdor, C.G.8    Punt, C.J.9    Adema, G.J.10
  • 23
    • 14044261257 scopus 로고    scopus 로고
    • Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation
    • 15728524
    • N.Schaft, J.Dörrie, P.Thumann, V.E.Beck, I.Müller, E.S.Schultz, E.Kämpgen, D.Dieckmann, G.Schuler. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005; 174:3087-3097; PMID:15728524; http://dx.doi.org/10.4049/jimmunol.174.5.3087
    • (2005) J Immunol , vol.174 , pp. 3087-3097
    • Schaft, N.1    Dörrie, J.2    Thumann, P.3    Beck, V.E.4    Müller, I.5    Schultz, E.S.6    Kämpgen, E.7    Dieckmann, D.8    Schuler, G.9
  • 24
    • 40749107482 scopus 로고    scopus 로고
    • Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells
    • 18157012
    • M.Javorovic, S.Wilde, A.Zobywalski, E.Noessner, V.Lennerz, T.Wölfel, D.J.Schendel. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J Immunother 2008; 31:52-62; PMID:18157012; http://dx.doi.org/10.1097/CJI.0b013e31815a1202
    • (2008) J Immunother , vol.31 , pp. 52-62
    • Javorovic, M.1    Wilde, S.2    Zobywalski, A.3    Noessner, E.4    Lennerz, V.5    Wölfel, T.6    Schendel, D.J.7
  • 25
    • 0035577861 scopus 로고    scopus 로고
    • Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals advances in brief bearing patients and healthy individuals 1
    • 11731409
    • R.H.Vonderheide et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals advances in brief bearing patients and healthy individuals 1. Cancer Res 2001; 61:8366-8370; PMID:11731409
    • (2001) Cancer Res , vol.61 , pp. 8366-8370
    • Vonderheide, R.H.1
  • 26
    • 0035881885 scopus 로고    scopus 로고
    • Spontaneous cytotoxic T-Cell responses against survivin-derived MHC Class I-restricted T-Cell epitopes in situ as well as ex vivo in cancer patients advances in brief as well as ex vivo in cancer patients 1
    • 11507035
    • M.H.Andersen, L.O.Pedersen, B.Capeller, E.B.Bröcker, J.C.Becker, P.Thor Straten. Spontaneous cytotoxic T-Cell responses against survivin-derived MHC Class I-restricted T-Cell epitopes in situ as well as ex vivo in cancer patients advances in brief as well as ex vivo in cancer patients 1. Cancer Res 2001; 61:5964-5968; PMID:11507035
    • (2001) Cancer Res , vol.61 , pp. 5964-5968
    • Andersen, M.H.1    Pedersen, L.O.2    Capeller, B.3    Bröcker, E.B.4    Becker, J.C.5    Thor Straten, P.6
  • 27
    • 84955701712 scopus 로고    scopus 로고
    • A randomized phase II clinical trial of personalized peptide vaccination with metronomic low dose cyclophosphamide in patients with metastatic castration resistant prostate cancer
    • 26728480
    • M.Noguchi, F.Moriya, N.Koga, S.Matsueda. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low dose cyclophosphamide in patients with metastatic castration resistant prostate cancer. Cancer Immunol Immunother 2016; 65:151-160; PMID:26728480; http://dx.doi.org/10.1007/s00262-015-1781-6
    • (2016) Cancer Immunol Immunother , vol.65 , pp. 151-160
    • Noguchi, M.1    Moriya, F.2    Koga, N.3    Matsueda, S.4
  • 28
    • 0347626100 scopus 로고    scopus 로고
    • Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model
    • 14679003
    • I.F.Hermans, T.W.Chong, M.J.Palmowski, A.L.Harris, V.Cerundolo. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63:8408-8413; PMID:14679003
    • (2003) Cancer Res , vol.63 , pp. 8408-8413
    • Hermans, I.F.1    Chong, T.W.2    Palmowski, M.J.3    Harris, A.L.4    Cerundolo, V.5
  • 29
    • 15944410592 scopus 로고    scopus 로고
    • + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
    • + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2013; 105:2862-2868; PMID:15591121; http://dx.doi.org/10.1182/blood-2004-06-2410
    • (2013) Blood , vol.105 , pp. 2862-2868
    • Lutsiak, M.E.1    Semnani, R.T.2    De Pascalis, R.3    Kashmiri, S.V.4    Schlom, J.5    Sabzevari, H.6
  • 30
    • 84938252275 scopus 로고    scopus 로고
    • T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
    • 26219463
    • F.M.Schnorfeil, F.S.Lichtenegger, K.Emmerig, M.Schlueter, J.S.Neitz, R.Draenert, W.Hiddemann, M.Subklewe. T cells are functionally not impaired in AML:increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 2015; 8:93; PMID:26219463; http://dx.doi.org/10.1186/s13045-015-0189-2
    • (2015) J Hematol Oncol , vol.8 , pp. 93
    • Schnorfeil, F.M.1    Lichtenegger, F.S.2    Emmerig, K.3    Schlueter, M.4    Neitz, J.S.5    Draenert, R.6    Hiddemann, W.7    Subklewe, M.8
  • 31
    • 84876478036 scopus 로고    scopus 로고
    • T cells from CLLpatients exhibit features of T-cell exhaustion but retain capacity for cytokine production
    • 23247726
    • J.C.Riches, J.K.Davies, F.McClanahan, R.Fatah, S.Iqbal, S.Agrawal, A.G.Ramsay, J.G.Gribben. T cells from CLLpatients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121:1612-1621; PMID:23247726; http://dx.doi.org/10.1182/blood-2012-09-457531
    • (2013) Blood , vol.121 , pp. 1612-1621
    • Riches, J.C.1    Davies, J.K.2    McClanahan, F.3    Fatah, R.4    Iqbal, S.5    Agrawal, S.6    Ramsay, A.G.7    Gribben, J.G.8
  • 33
    • 84921648852 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
    • 25960932
    • G.M.Weir, O.Hrytsenko, M.M.Stanford, N.L.Berinstein, M.Karkada, R.S.Liwski, M.Mansour. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology 2014; 3:e953407; PMID:25960932; http://dx.doi.org/10.4161/21624011.2014.953407
    • (2014) Oncoimmunology , vol.3 , pp. e953407
    • Weir, G.M.1    Hrytsenko, O.2    Stanford, M.M.3    Berinstein, N.L.4    Karkada, M.5    Liwski, R.S.6    Mansour, M.7
  • 34
    • 84866697418 scopus 로고    scopus 로고
    • Cellular based cancer vaccines: type 1 polarization of dendritic cells
    • 22834814
    • M.Hansen, Ö.Met, I.M.Svane, M.H.Andersen. Cellular based cancer vaccines:type 1 polarization of dendritic cells. Curr Med Chem 2012; 19:4239-46; PMID:22834814; http://dx.doi.org/10.2174/092986712802884213
    • (2012) Curr Med Chem , vol.19 , pp. 4239-4246
    • Hansen, M.1    Met, Ö.2    Svane, I.M.3    Andersen, M.H.4
  • 40
    • 84875442610 scopus 로고    scopus 로고
    • HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients
    • 23328583
    • S.Munir, G.H.Andersen, Ö.Met, M.Donia, T.M.Frøsig, S.K.Larsen, T.W.Klausen, I.M.Svane, M.H.Andersen. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 2013; 73:1764-1776; PMID:23328583; http://dx.doi.org/10.1158/0008-5472.CAN-12-3507
    • (2013) Cancer Res , vol.73 , pp. 1764-1776
    • Munir, S.1    Andersen, G.H.2    Met, Ö.3    Donia, M.4    Frøsig, T.M.5    Larsen, S.K.6    Klausen, T.W.7    Svane, I.M.8    Andersen, M.H.9
  • 41
    • 84922074156 scopus 로고    scopus 로고
    • Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology
    • M.H.Andersen. Potential roles of self-reactive T cells in autoimmunity:lessons from cancer immunology. Immunol Res 2014; 60(2-3):156-64; PMID:25381479; http://dx.doi.org/10.1007/s12026-014-8559-3
    • (2014) Immunol Res , vol.60 , Issue.2-3 , pp. 156-164
    • Andersen, M.H.1
  • 42
    • 84891840810 scopus 로고    scopus 로고
    • Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
    • 24091833
    • S.M.Ahmad, S.K.Larsen, I.M.Svane, M.H.Andersen. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 2014; 28:236-8; PMID:24091833; http://dx.doi.org/10.1038/leu.2013.261
    • (2014) Leukemia , vol.28 , pp. 236-238
    • Ahmad, S.M.1    Larsen, S.K.2    Svane, I.M.3    Andersen, M.H.4
  • 43
    • 84963629041 scopus 로고    scopus 로고
    • Phase II study of autologous monocyte-derived mrna electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma
    • 26926680
    • S.Wilgenhof, J.Corthals, C.Heirman, N.van Baren, S.Lucas, P.Kvistborg, K.Thielemans, B.Neyns. Phase II study of autologous monocyte-derived mrna electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 2016; 34(12):1330-8; PMID:26926680; http://dx.doi.org/10.1200/JCO.2015.63.4121
    • (2016) J Clin Oncol , vol.34 , Issue.12 , pp. 1330-1338
    • Wilgenhof, S.1    Corthals, J.2    Heirman, C.3    van Baren, N.4    Lucas, S.5    Kvistborg, P.6    Thielemans, K.7    Neyns, B.8
  • 44
    • 0036133166 scopus 로고    scopus 로고
    • mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)
    • S.Sæbøe-Larssen, E.Fossberg, G.Gaudernack. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002; 259:191-203; PMID:11730854; http://dx.doi.org/10.1016/S0022-1759(01)00506-3
    • (2002) J Immunol Methods , vol.259 , pp. 191-203
    • Sæbøe-Larssen, S.1    Fossberg, E.2    Gaudernack, G.3
  • 45
    • 84988860683 scopus 로고    scopus 로고
    • Immune monitoring using mRNA-Transfected dendritic cells
    • 27236804
    • T.H.Borch, I.M.Svane, Ö.Met. Immune monitoring using mRNA-Transfected dendritic cells. Methods Mol Biol 2016; 1428:245-59; PMID:27236804; http://dx.doi.org/10.1007/978-1-4939-3625-0_16
    • (2016) Methods Mol Biol , vol.1428 , pp. 245-259
    • Borch, T.H.1    Svane, I.M.2    Met, Ö.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.